NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/10/2024
Back to search
Official data from USPTO
ALIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
09/10/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
08/31/2021
Registration date
09/10/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/10/2024
Last transaction
09/10/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Ciudad de México, MX
Examiner
WOLD, BARBARA NIELSEN
Law office
M50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Productos Farmaceuticos S.A. de C.V.
Representatives
Jennifer A. Van Kirk LEWIS ROCA ROTHGERBER CHRISTIE LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasendocrinology for treatment of adrenal failurethyroiditis; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasrheumatology for treatment of rheumatoid arthritisgoutpost-traumatic arthritisosteoarthritissynovitisbursitisepicondylitisankylosing spondylitissystemic or discoid lupus erythematosusdermatomyositissclerodermaother collagen diseasesother osteoarticular diseases which require chronic corticosteroid administration; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasdermatology for treatment of pemphiguserythema multiformeexfoliative dermatitispsoriasiscontact dermatitiskeloid lesionshyperthrophic lichen planusalopecia areataurticariaeczemarosacea; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasallergology for treatment of bronchial asthmaurticariadrug or food allergyhypersensitivity reactionsallergic rhinitisallergic sinusitis; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasotolaryngology for treatment of vasomotor rhinitisother types of rhinitis; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasophthalmology for treatment of allergicacute or chronic conjunctivitisscleritisuveitisiridocyclitisoptic neuritiscorneal infectionskeratitismarginal ulcersthrophic disordersconjunctivalcorneal physicalchemical burninginflammatory reactions; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasgastroenterology for treatment of ulcerative colitisregional enteritis; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areaspulmonology for treatment of bronchoaspirationLöeffler syndromesarcoidosisinterstitial pulmonary fibrosischronic bronchitisemphysema; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areashematology for treatment of autoimmune anemias or thrombocytopeniasleukemiaslymphomasintravascular coagulation syndrome; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasoncology for treatment of nausea and vomiting associated with cancer chemotherapy prevention; Pharmaceutical preparationscorticosteroid with anti-inflammatoryimmunosuppressive and anti-allergic actionsalone or in combination with other active pharmaceutical principlesfor use in different therapeutic areasmiscellaneous for treatment of shock syndromescerebral edema
Publications
History of USPTO decisions and trademark events.
28 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/25/2024
PUBO
PUBLISHED FOR OPPOSITION
06/25/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/17/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/30/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/30/2024
ALIE
ASSIGNED TO LIE
04/30/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/11/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/29/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/29/2023
CNSI
SUSPENSION INQUIRY WRITTEN
11/29/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/01/2023
GNSL
LETTER OF SUSPENSION E-MAILED
06/01/2023
CNSL
SUSPENSION LETTER WRITTEN
06/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/31/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/30/2023
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
11/30/2022
GPRA
PRIORITY ACTION E-MAILED
11/30/2022
CPRA
PRIORITY ACTION WRITTEN
11/30/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/04/2022
GNRT
NON-FINAL ACTION E-MAILED
06/04/2022
CNRT
NON-FINAL ACTION WRITTEN
06/04/2022
DOCK
ASSIGNED TO EXAMINER
06/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/14/2021
NWAP
NEW APPLICATION ENTERED
09/03/2021
Continuous trademark protection
Get notified about every new filing that threatens ALIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.